Clover Biopharmaceuticals, Ltd.

SEHK:2197 Stock Report

Market Cap: HK$363.2m

Clover Biopharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Clover Biopharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth42.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth

Mar 17
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth

Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?

Nov 29
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?

Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?

Aug 31
Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?

We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely

Apr 28
We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely

Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate

Feb 05
Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Clover Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2197 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202429-884-462-455N/A
3/31/202434-511-599-592N/A
12/31/202339-139-737-728N/A
9/30/202320-402-1,174-1,145N/A
6/30/20230-665-1,610-1,562N/A
3/31/20230-1,559-1,703-1,627N/A
12/31/2022N/A-2,452-1,796-1,691N/A
9/30/2022N/A-4,145-1,461-1,356N/A
6/30/2022N/A-5,838-1,125-1,021N/A
3/31/2022N/A-5,927-1,062-969N/A
12/31/2021N/A-6,016-998-918N/A
12/31/2020N/A-913363477N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2197's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2197's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2197's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2197's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2197's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2197's Return on Equity is forecast to be high in 3 years time


Discover growth companies